Cargando…
A Review of Switching Strategies for Patients with Schizophrenia Comorbid with Metabolic Syndrome or Metabolic Abnormalities
Metabolic syndrome (MetS) in patients with schizophrenia occurs 2–3 times more frequently than in the general population. Antipsychotic medication is a primary risk factor for patients with MetS. In particular, the widely used second-generation antipsychotics can affect glucose and lipid metabolism...
Autores principales: | Liao, Xuemei, Ye, Hui, Si, Tianmei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7884949/ https://www.ncbi.nlm.nih.gov/pubmed/33603382 http://dx.doi.org/10.2147/NDT.S294521 |
Ejemplares similares
-
The metabolic syndrome and schizophrenia: A comorbidity or an association?
por: khalil, Rami Bou
Publicado: (2013) -
Effectiveness and Safety of Switching from Oral Antipsychotics to Once-Monthly Paliperidone Palmitate (PP1M) in the Management of Schizophrenia: A Systematic Review and Meta-Analysis
por: Li, Qian, et al.
Publicado: (2023) -
Dose-Dependent Efficacy of Aripiprazole in Treating Patients With Schizophrenia or Schizoaffective Disorder: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Qian, Li, et al.
Publicado: (2021) -
Metabolic syndrome in schizophrenia
por: Malhotra, Nidhi, et al.
Publicado: (2013) -
Metabolic Abnormalities in Glioblastoma and Metabolic Strategies to Overcome Treatment Resistance
por: Zhou, Weihua, et al.
Publicado: (2019)